FDA Approves DAPSONE — Viona Pharmaceuticals Inc

# FDA Approves Viona Pharmaceuticals' Generic Dapsone Viona Pharmaceuticals Inc. received FDA approval for its generic dapsone oral formulation, expanding treatment options for patients with dermatitis herpetiformis and leprosy while potentially increasing pricing competition in the dermatological antibiotic market. The approval of the ANDA 220103 application is expected to provide healthcare systems with more cost-effective alternatives to branded versions of the antibiotic.